These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 25281420)

  • 1. Modeling cancer-immune responses to therapy.
    dePillis LG; Eladdadi A; Radunskaya AE
    J Pharmacokinet Pharmacodyn; 2014 Oct; 41(5):461-78. PubMed ID: 25281420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery.
    Creemers JHA; Lesterhuis WJ; Mehra N; Gerritsen WR; Figdor CG; de Vries IJM; Textor J
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34059522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Systems Pharmacology Approaches for Immuno-Oncology: Adding Virtual Patients to the Development Paradigm.
    Chelliah V; Lazarou G; Bhatnagar S; Gibbs JP; Nijsen M; Ray A; Stoll B; Thompson RA; Gulati A; Soukharev S; Yamada A; Weddell J; Sayama H; Oishi M; Wittemer-Rump S; Patel C; Niederalt C; Burghaus R; Scheerans C; Lippert J; Kabilan S; Kareva I; Belousova N; Rolfe A; Zutshi A; Chenel M; Venezia F; Fouliard S; Oberwittler H; Scholer-Dahirel A; Lelievre H; Bottino D; Collins SC; Nguyen HQ; Wang H; Yoneyama T; Zhu AZX; van der Graaf PH; Kierzek AM
    Clin Pharmacol Ther; 2021 Mar; 109(3):605-618. PubMed ID: 32686076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.
    Ducry L; Stump B
    Bioconjug Chem; 2010 Jan; 21(1):5-13. PubMed ID: 19769391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the understanding of cancer immunotherapy.
    Shore ND
    BJU Int; 2015 Sep; 116(3):321-9. PubMed ID: 24612369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Antibodies in Cancer Therapy.
    Gasser M; Waaga-Gasser AM
    Adv Exp Med Biol; 2016; 917():95-120. PubMed ID: 27236554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-based immunotherapy of solid cancers: progress and possibilities.
    Nicodemus CF
    Immunotherapy; 2015; 7(8):923-39. PubMed ID: 26314410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing Chemotherapeutic Anti-cancer Treatment and the Tumor Microenvironment: An Analysis of Mathematical Models.
    Ledzewicz U; Schaettler H
    Adv Exp Med Biol; 2016; 936():209-223. PubMed ID: 27739050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer immunology and melanoma immunotherapy.
    Linck RDM; Costa RLP; Garicochea B
    An Bras Dermatol; 2017; 92(6):830-835. PubMed ID: 29364441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer immunotherapy: the beginning of the end of cancer?
    Farkona S; Diamandis EP; Blasutig IM
    BMC Med; 2016 May; 14():73. PubMed ID: 27151159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging Opportunities and Challenges in Cancer Immunotherapy.
    Whiteside TL; Demaria S; Rodriguez-Ruiz ME; Zarour HM; Melero I
    Clin Cancer Res; 2016 Apr; 22(8):1845-55. PubMed ID: 27084738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer immunotherapy, mathematical modeling and optimal control.
    Castiglione F; Piccoli B
    J Theor Biol; 2007 Aug; 247(4):723-32. PubMed ID: 17543345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination immunotherapy approaches.
    Drake CG
    Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii41-6. PubMed ID: 22918927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative.
    Peggs KS; Segal NH; Allison JP
    Cancer Cell; 2007 Sep; 12(3):192-9. PubMed ID: 17785201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitigating the toxic effects of anticancer immunotherapy.
    Gangadhar TC; Vonderheide RH
    Nat Rev Clin Oncol; 2014 Feb; 11(2):91-9. PubMed ID: 24445516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral immunotherapy: using the tumor as the remedy.
    Marabelle A; Tselikas L; de Baere T; Houot R
    Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy of cancer.
    Borghaei H; Smith MR; Campbell KS
    Eur J Pharmacol; 2009 Dec; 625(1-3):41-54. PubMed ID: 19837059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Immunotherapy and Targeted Therapies for Cancer Treatment: Recent Advances and Future Perspectives.
    Zhang Y; Li Y; Fu Q; Han Z; Wang D; Umar Shinge SA; Muluh TA; Lu X
    Curr Cancer Drug Targets; 2023; 23(4):251-264. PubMed ID: 36278447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.